Castle Biosciences, Inc. $CSTL Shares Sold by UBS Group AG
UBS Group AG reduced its stake in Castle Biosciences (NASDAQ:CSTL) by 51.3% in the fourth quarter, although it still retains a significant holding. Institutional ownership of Castle Biosciences remains high at 92.6%, despite recent insider sales by the CFO and another insider. The company reported mixed first-quarter results with earnings matching expectations but revenue exceeding estimates; shares are currently trading well below their 52-week high.
Portolan Capital amends Castle Biosciences (NASDAQ: CSTL) 13G; 4.45% stake reported
Portolan Capital Management, LLC and George McCabe have filed an amended Schedule 13G, disclosing a 4.45% beneficial ownership stake in Castle Biosciences (NASDAQ: CSTL). As of March 31, 2026, they hold 1,350,283 shares with sole voting and dispositive power. The amendment, signed on May 15, 2026, indicates a passive investment below the 5% threshold, with no stated intent to influence control.
RTW Funds own 2.76M Castle Biosciences shares (CSTL) — 9.3% stake
RTW Investments, LP and Roderick Wong have reported beneficial ownership of 2,758,335 shares of Castle Biosciences (CSTL), representing a 9.3% stake. This information comes from an amended Schedule 13G/A filing. The shares are directly held by RTW Funds, with shared voting and dispositive power, and the percentage is based on Castle Biosciences' outstanding share count as of February 19, 2026.
Castle Biosciences, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:CSTL) 2026-05-13
Castle Biosciences, Inc. released its Q1 2026 earnings, reporting an EPS of -$0.49, which missed estimates by $0.00. The company's revenue was $83.68M, a 4.90% year-over-year decrease, but still beat expectations by $4.45M. This article refers to the slide deck published in conjunction with their earnings call.
CSTL Maintained by BTIG -- Price Target Lowered to $40.00
BTIG analyst Mark Massaro has maintained a 'Buy' rating for Castle Biosciences (CSTL) but lowered its price target from $50.00 to $40.00, reflecting a 20% decrease. GuruFocus indicates that CSTL is currently undervalued by 35.8% with a GF Value™ of $29.04, despite a GF Score™ of 78/100, strong financial strength, and growth potential. However, insider selling activity totaling $3.1 million in the past three months suggests caution for investors.
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that its executive management will present a company overview at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 1:20 p.m. Eastern time. A live audio webcast will be available on the company's website, with a replay accessible after the broadcast. The company specializes in innovative diagnostic tests for dermatologic and gastroenterological diseases.
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
Castle Biosciences' AdvanceAD-Tx™ test has received the 2026 MedTech Breakthrough Award for Genomics Innovation, marking the fifth such award for the company. The AdvanceAD-Tx test is a clinically validated gene expression profile (GEP) test designed to guide systemic treatment decisions for patients aged 12 and older with moderate-to-severe atopic dermatitis (AD) by utilizing a non-invasive skin scraping to analyze gene expression. This award recognizes the test's ability to provide objective, molecularly guided insights, helping clinicians select therapies that can improve patient outcomes by personalizing treatment based on an individual's immune profile.
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares
Derek Maetzold, CEO of Castle Biosciences Inc., recently sold 9,036 shares of common stock for a total of $217,904 and acquired 6,214 shares valued at $14,851 through stock option exercises, all under a Rule 10b5-1 trading plan. The sales involved shares held directly and indirectly through various family trusts. Despite the sales, Maetzold maintains significant direct and indirect holdings in the company, which InvestingPro analysis suggests is undervalued with a good financial health score.
Derek Maetzold, Castle Biosciences CEO, sells $217,904 in shares
Derek Maetzold, CEO of Castle Biosciences Inc. (NASDAQ:CSTL), sold $217,904 worth of company shares and acquired $14,851 worth through option exercises on May 7, 2026. These transactions were executed under a Rule 10b5-1 trading plan established on December 3, 2025, and included both direct and indirect sales via various family trusts. The article also touches upon Castle Biosciences' strong Q1 2026 earnings, reporting $83.7 million in revenue.
Castle Biosciences (CSTL) CEO sells shares and exercises stock options in pre-planned trades
Castle Biosciences CEO Derek J. Maetzold reported exercising stock options for 6,214 shares and selling 9,836 shares of CSTL common stock in pre-planned transactions on May 7, 2026. These trades, conducted both directly and through various family trusts, were executed under a Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Maetzold continues to hold a significant number of shares directly and indirectly, indicating routine liquidity and portfolio management rather than a change in investment thesis.
Castle Biosciences (NASDAQ:CSTL) Cut to "Sell" at Wall Street Zen
Castle Biosciences (NASDAQ:CSTL) was downgraded to "sell" by Wall Street Zen, despite other analysts maintaining more positive ratings. The company's recent earnings met EPS expectations while exceeding revenue forecasts. Notably, several insiders, including CEO Derek J. Maetzold, have sold shares in recent months.
Castle Biosciences (CSTL) Q1 Loss Of US$14.5 Million Tests Profitability Narrative
Castle Biosciences (CSTL) reported a Q1 2026 loss of US$14.5 million, with basic EPS at a loss of US$0.49, despite revenues of US$83.7 million. This performance highlights ongoing challenges in achieving profitability, contrasting with analyst expectations of future growth and margin improvements. The article explores the "bull" and "bear" cases for the company, noting that current results don't yet reflect the required shift towards profitability to support optimistic valuations.
Castle Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since July 2024 -- Data Talk
Castle Biosciences (CSTL) is experiencing a significant stock decrease of over 15%, marking its largest single-day percentage drop since July 2024. The company's stock volume is currently triple its 65-day average, indicating high trading activity amidst the decline. This downturn has brought the stock price to below its 50-day moving average and could push it towards levels not seen since April.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2026 Earnings Call Transcript
Castle Biosciences, Inc. announced strong Q1 2026 results, reporting revenue of $83.7 million and raising its full-year 2026 revenue guidance to between $345 million and $355 million. The growth was primarily driven by DecisionDx-Melanoma and TissueCypher tests, with test report volumes for core revenue drivers increasing by 36% year-over-year. The company also highlighted positive clinical validation data for its Advanced ADTx test and provided updates on reimbursement initiatives and M&A considerations.
Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL): Here's what you should know
This article highlights that Wall Street analysts project a significant 85.15% upside for Castle Biosciences (CSTL). It aims to inform readers about the company's prospects based on analyst expectations, indicating potential growth.
Derek Maetzold files Form 144 to sell CSTL (NASDAQ: CSTL) shares
Derek Maetzold has filed a Form 144 detailing proposed and recent sales of Common stock in Castle Biosciences (NASDAQ: CSTL). The filing reports significant open-market disposals, including for $584,548.88 on 03/12/2026 and $482,441.93 on 03/17/2026, alongside other trust-held share dispositions throughout March and April 2026. This SEC filing provides transparency regarding the insider's transactions and clarifies the nature of a Form 144, which is required for large stock sales that could impact the market.
Castle Biosciences (NASDAQ:CSTL) Price Target Lowered to $43.00 at Robert W. Baird
Robert W. Baird has lowered its price target for Castle Biosciences (NASDAQ:CSTL) to $43.00 from $44.00, while maintaining an "outperform" rating, indicating a potential upside of 73.7% from its current price. Despite the reduction, the consensus among analysts is a "Moderate Buy" with an average target of $46.00. The company recently reported Q1 EPS of ($0.49) in line with estimates and revenue of $84.2 million, exceeding expectations.
Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders
Castle Biosciences is projecting revenues between $345 million and $355 million for 2026, driven by significant growth in its TissueCypher volumes, which increased by 58%, and the considerable uptake of its AdvanceAD-Tx test, reaching approximately 650 orders. This guidance suggests a positive outlook for the company's diagnostic offerings.
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results, Hits Expectations
Castle Biosciences (NASDAQ:CSTL) announced Q1 earnings, matching EPS estimates at ($0.49) and exceeding revenue expectations with $84.23 million. The company raised its 2026 revenue guidance to $345–$355 million, driven by strong core test volume growth and early commercial traction for its AdvanceAD-Tx test. Despite narrowing net losses, adjusted EBITDA remained negative, though the company maintains a strong cash position and strategic growth plans.
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Castle Biosciences, Inc. (CSTL) reported a Q1 loss of $0.49 per share, beating the Zacks Consensus Estimate of a $0.56 loss. The company's revenues were $83.68 million, surpassing estimates by 2.65%, though lower than the previous year. Despite underperforming the market year-to-date, Castle Biosciences currently holds a Zacks Rank #1 (Strong Buy) reflecting a favorable earnings outlook.
Earnings Flash (CSTL) Castle Biosciences, Inc. Posts Q1 Adjusted Loss $0.49 per Share, vs. FactSet Est of $-0.49
Castle Biosciences, Inc. reported an adjusted loss of $0.49 per share for the first quarter, matching FactSet's estimate. This financial update follows an earlier announcement where the company exceeded revenue expectations, reporting $83.7 million against an estimate of $79.2 million. The information highlights key financial performance indicators for the molecular diagnostics company.
Earnings Flash (CSTL) Castle Biosciences, Inc. Reports Q1 Revenue $83.7M, vs. FactSet Est of $79.2M
Castle Biosciences, Inc. announced Q1 revenue of $83.7 million, surpassing the FactSet estimate of $79.2 million. This financial update highlights the company's performance in the first quarter of 2026. Further details of this article are reserved for members.
Castle Biosciences Reports First Quarter 2026 Results
Castle Biosciences reported strong first quarter 2026 results with $83.7 million in revenue and a 36% increase in core test reports (DecisionDx-Melanoma and TissueCypher) compared to Q1 2025. The company raised its full-year 2026 revenue guidance to $350-$360 million from $320-$330 million, reflecting confidence in its performance. Significant clinical data presentations reinforced the value of their dermatologic and gastroesophageal tests, supporting personalized patient care.
Castle Biosciences Reports First Quarter 2026 Results
Castle Biosciences (Nasdaq: CSTL) announced strong first-quarter 2026 financial results, with revenues of $83.7 million and a 36% increase in test reports for core revenue drivers, DecisionDx-Melanoma and TissueCypher, over Q1 2025. The company raised its full-year 2026 revenue guidance to $345-355 million and highlighted advancements in its dermatology and gastroenterology diagnostic tests, including new data supporting DecisionDx-Melanoma's efficacy and the publication of a clinical validation study for AdvanceAD-Tx.
Castle Biosciences (NASDAQ: CSTL) lifts 2026 outlook after Q1 core test growth
Castle Biosciences reported Q1 2026 results, with revenue of $83.7 million, a slight decrease from the prior year, but core test volumes for DecisionDx-Melanoma and TissueCypher grew significantly by 16% and 58% respectively. The company raised its full-year 2026 revenue guidance to $345–355 million from the previous $340–350 million, citing strong test adoption and expanding clinical evidence. Despite reporting a net loss of $14.5 million and Adjusted EBITDA of $(5.1) million, the company maintains a strong cash position of $261.7 million, with management expressing confidence in continued growth.
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
Castle Biosciences is observing Skin Cancer Awareness Month in May 2026 by supporting various nationwide initiatives. These efforts, in collaboration with organizations like AIM at Melanoma, the Melanoma Research Foundation, and The Skin Cancer Foundation, focus on increasing awareness, facilitating early detection through screenings, and providing patient education to improve outcomes. The company will participate in advocacy walks, community screenings, and educational programs across the U.S.
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
Wall Street analysts predict an 85.15% upside in Castle Biosciences (CSTL), with a mean price target of $47.25. Despite the skepticism surrounding price targets, the company's strong Zacks Rank #1 (Strong Buy) and positive earnings estimate revisions suggest potential for near-term upside. Investors are advised to use price targets as a starting point for research rather than the sole basis for investment decisions.
Free skin cancer screenings roll out nationwide with Castle support
Castle Biosciences (CSTL) is actively supporting Skin Cancer Awareness Month in May 2026 through various nationwide initiatives. These include patient advocacy walks, community screenings, educational symposiums, and a webinar, in collaboration with several patient-focused organizations. The company aims to advance early detection, patient education, and advocacy to improve outcomes for skin cancer patients.
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
Castle Biosciences is participating in various nationwide initiatives during Skin Cancer Awareness Month in May, collaborating with patient advocacy organizations like AIM at Melanoma, Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma, and The Sun Bus. These efforts include advocacy walks, free community skin cancer screenings, and patient education programs, reinforcing the company's commitment to early detection and improving patient outcomes. The initiatives aim to expand access to skin cancer education and resources, supporting prevention, early detection, and enhanced patient care.
Castle Biosciences to present new Mayo Clinic research on TissueCypher test at Digestive Disease Week
Castle Biosciences will present new research on its TissueCypher test at Digestive Disease Week in Chicago, developed in partnership with Mayo Clinic. The studies will highlight the test's role in improving molecular risk stratification for patients with digestive disorders, aiming for more accurate risk assessment and targeted patient management. This presentation builds on Castle Biosciences' previous emphasis on the contributions of its laboratory teams to diagnostic innovation.
Mayo Clinic data: Barrett's test changed surveillance in 55%
Castle Biosciences announced new Mayo Clinic data presented at Digestive Disease Week 2026, highlighting that its TissueCypher test significantly refined risk stratification and guided surveillance decisions for patients with Barrett's esophagus. The data showed that physicians altered surveillance intervals in 55% of patients and aligned recommendations with TissueCypher risk classification in 79% of cases. The findings suggest that TissueCypher provides more accurate insights than traditional clinical risk assessments, enabling more personalized and risk-aligned patient management.
Castle Biosciences (NASDAQ:CSTL) Upgraded to Strong-Buy at Zacks Research
Zacks Research has upgraded Castle Biosciences (NASDAQ:CSTL) to a "strong-buy" rating, reflecting a positive outlook from several analyst firms. Despite recent insider share sales, institutional investors hold a significant portion of the company. Castle Biosciences reported an EPS beat and exceeded revenue expectations, though it maintains a negative P/E ratio.
Castle Biosciences (CSTL) to Release Earnings on Wednesday
Castle Biosciences (CSTL) is scheduled to release its Q1 2026 earnings after market close on Wednesday, May 6th. Analysts anticipate an EPS of ($0.4888) and revenue of $79.284 million. The company currently holds a "Moderate Buy" consensus rating with an average target price of $46.14, despite recent insider share sales.
Castle Biosciences (NASDAQ: CSTL) CEO sells 4,172 shares via trusts
Castle Biosciences CEO Derek Maetzold sold a total of 4,172 shares of common stock at a weighted-average price of $25.098 per share on April 21, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Concurrently, Maetzold exercised stock options to acquire 550 shares at $2.39 per share, selling a matching number of shares. After these transactions, Maetzold directly holds 21,479 shares, with additional indirect holdings through various family trusts.
Castle Biosciences (NASDAQ:CSTL) Shares Gap Down on Insider Selling
Castle Biosciences (NASDAQ:CSTL) shares gapped down following the disclosure of an insider sale by Director Derek J. Maetzold, who sold 3,622 shares under a Rule 10b5-1 plan, reducing his ownership by 59.14%. Despite this, the company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $46.14, and recently beat revenue and EPS estimates in its latest quarterly report.
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that it will release its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will also host a webcast at 4:30 p.m. Eastern time on the same day to discuss the results, followed by a Q&A session. Castle Biosciences is a diagnostics company focused on dermatologic and gastroenterological diseases.
Castle Biosciences CEO Maetzold sells $104,708 in shares By Investing.com
Castle Biosciences CEO Derek J. Maetzold recently sold 4,150 shares of the company's common stock for approximately $104,708 through a Rule 10b5-1 trading plan. This transaction occurred amidst a challenging year for the stock, which has fallen 35% year-to-date, though analysts indicate the stock may be undervalued. Concurrently, Maetzold also acquired 550 shares by exercising stock options.
Castle Biosciences CEO Maetzold sells $104,708 in shares By Investing.com
Castle Biosciences CEO Derek J. Maetzold recently sold 4,150 shares of common stock totaling approximately $104,708 through direct sales and various trusts, while also acquiring 550 shares through vested stock options. These transactions, conducted under a Rule 10b5-1 trading plan, follow a period where the stock has declined 35% year-to-date, despite the company surpassing Q4 2025 earnings and revenue expectations and analysts setting price targets significantly higher than current levels.
Castle Biosciences (NASDAQ:CSTL) Insider Sells $90,912.20 in Stock
Castle Biosciences (NASDAQ:CSTL) insider Derek Maetzold sold 3,622 shares of the company's stock valued at $90,912.20 on April 21st, reducing his direct ownership by 59.14%. Despite the insider sell-off, the company reported an EPS beat and analysts have a "Moderate Buy" rating with a consensus price target of $46.14. Institutional investors hold a significant 92.6% of the shares.
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Cuts Target Price to $40
CCORF has reiterated its Buy rating for Castle Biosciences (CSTL.US) but has lowered its target price to $40. This adjustment in target price indicates a revised outlook on the stock's potential, while the maintained Buy rating suggests continued confidence in the company's long-term prospects.
New data suggest some early melanomas carry higher relapse risk
Castle Biosciences will present new data at upcoming medical conferences (EADO and ACMS) demonstrating that its DecisionDx-Melanoma test can identify patients with early-stage melanoma, including thin tumors, who are at a higher risk of recurrence and poor outcomes. This test provides prognostic information beyond traditional AJCC staging, enabling more personalized and risk-aligned clinical management. The findings are based on a large multi-center cohort and a SEER population study, highlighting the test's ability to help clinicians make more informed treatment decisions.
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Castle Biosciences announced new data presentations for its DecisionDx-Melanoma test at the EADO Congress and ACMS 58th Annual Meeting. The data highlights the test's ability to identify early-stage melanoma patients at higher risk of recurrence and poor outcomes, whose risk may be underestimated by traditional staging. This personalized information guides more precise, risk-aligned clinical management, including decisions related to sentinel lymph node biopsy and surveillance intensity.
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Castle Biosciences announced new data presentations for its DecisionDx-Melanoma test at the EADO Congress and ACMS 58th Annual Meeting. The data highlight the test's ability to identify early-stage melanoma patients at higher risk of recurrence and poor outcomes, thereby aiding more precise clinical management. These findings demonstrate that the test refines risk assessment beyond traditional AJCC staging, particularly for patients with thin tumors.
Laboratory teams drive progress in skin cancer diagnostics at Castle Biosciences
Castle Biosciences is celebrating its laboratory professionals during Lab Week, acknowledging their vital contributions to innovative diagnostic tests for skin cancer. The company highlights its lab teams' role in providing personalized information that enhances patient care and improves health outcomes. This recognition coincides with Castle Biosciences unveiling its new headquarters in Friendswood, Texas, underscoring its commitment to growth and community.
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Moderate Buy" by Analysts
Castle Biosciences, Inc. (NASDAQ:CSTL) has received a "Moderate Buy" consensus rating from ten research firms, with an average one-year price target of $47.57. Recent analyst upgrades and raised price targets include actions from Morgan Stanley, Lake Street, Canaccord, and Guggenheim. The company recently beat quarterly earnings and revenue estimates, though insiders have sold a significant number of shares totaling approximately $2.16 million in the last 90 days.
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Company management will host a webcast at 4:30 p.m. Eastern time on the same day to discuss the results. The live webcast details are provided, along with information about Castle Biosciences, a diagnostics company focused on dermatologic and gastroenterological diseases.
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its financial results for the first quarter ended March 31, 2026, after market close on Wednesday, May 6, 2026. The company will also host a webcast at 4:30 p.m. Eastern time on the same day to discuss the results, followed by a brief Q&A session. A replay of the webcast will be available on the company's investor relations website.
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences, Inc. (Nasdaq: CSTL) announced it will release its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will also host a webcast at 4:30 p.m. Eastern time on the same day to discuss these results. Castle Biosciences focuses on innovative tests to guide patient care in dermatologic and gastroenterological diseases.
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Castle Biosciences (Nasdaq: CSTL) announced it will release its first quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will also host a live webcast at 4:30 p.m. ET on the same day, which will include a brief Q&A session. Investors can access the webcast via the provided link or the company's Investor Relations page.
[ARS] CASTLE BIOSCIENCES INC SEC Filing
This article announces an ARS SEC filing by Castle Biosciences Inc. (CSTL) on April 8, 2026, categorized with a low impact and neutral sentiment. It provides details about the filing, including its type and acceptance date, and links to the full PDF document and original filing on SEC EDGAR. The article also includes current stock data for CSTL, such as market cap and rankings, alongside recent news and other SEC filings related to the company.
